Squarepoint’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Squarepoint’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-12,406	Closed	-$85K	–	3604
2021 Q2	$85K	Buy	+12,406	New	+$100K	﹤0.01%	3046
2020 Q4	–	Sell	-31,187	Closed	-$169K	–	3366
2020 Q3	$169K	Sell	31,187 -95,162	-75%	-$471K	﹤0.01%	2156
2020 Q2	$660K	Buy	+126,349	New	+$561K	0.01%	1155
2020 Q1	–	Sell	-25,511	Closed	-$103K	–	2696
2019 Q4	$103K	Buy	+25,511	New	+$88.5K	﹤0.01%	2344
2018 Q4	–	Sell	-10,347	Closed	-$100K	–	2321
2018 Q3	$100K	Buy	+10,347	New	+$104K	﹤0.01%	1885
2018 Q2	–	Sell	-15,600	Closed	-$203K	–	2134
2018 Q1	$203K	Sell	15,600 -14,522	-48%	-$216K	﹤0.01%	1487
2017 Q4	$539K	Buy	+30,122	New	+$629K	0.01%	1162
2017 Q1	–	Sell	-17,813	Closed	-$274K	–	1997
2016 Q4	$274K	Buy	+17,813	New	+$231K	0.01%	1207
2016 Q3	–	Sell	-22,400	Closed	-$312K	–	1323
2016 Q2	$312K	Buy	+22,400	New	+$330K	0.02%	714

Other funds holding PRTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's PRTK Position: Q3 2021 in Review

Squarepoint sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2021, closing a stake of 12,406 shares — an estimated $85K sold.

Squarepoint first reported a position in PRTK in Q2 2016 and held it in 9 quarters. The position peaked at $660K in Q2 2020. 105 funds tracked by Wall St. Rank hold PRTK as of Q3 2021.

Squarepoint reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Squarepoint sold 12,406 Paratek Pharmaceuticals, Inc. shares in Q3 2021, an estimated $85K.
Squarepoint first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2016 and held it in 9 quarters.
Squarepoint's Paratek Pharmaceuticals, Inc. position peaked at $660K in Q2 2020.
105 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2021.

Based on Squarepoint's 13F filing for Q3 2021, filed 15 Nov 2021.